Synairgen set for worst day after inhalable drug fails COVID study
21/02/2022 08:42
** Shares in British drugmaker SYNG.L tumble as much as
93.5% to 11.12p; set for worst day on record, if losses hold
** Says SNG001, its inhalable therapy, failed an
international late-stage trial testing the drug in hospitalised
COVID-19 patients urn:newsml:reuters.com:*:nL4N2UW1WX
** "While we are disappointed by the overall outcome, SNG001
has been administered to hospitalised patients on top of
standard of care which changed substantially between our Phase 2
and Phase 3 trials," co says
** Adds that it is now analysing full dataset from trial
** SYNG hits lowest level since Feb 2020
** Stock rose ~36% in 2021
(Reporting by Amna Karimi in Bengaluru)
((amna.karimi@thomsonreuters.com))